Skip to content

To evaluate the effect of Masquelet technique combined with BMP-2 loaded artificial bone, antibiotic loaded artificial bone and autologous bone mixed grafting in the treatment of infected nonunion in different parts

To evaluate the effect of Masquelet technique combined with BMP-2 loaded artificial bone, antibiotic loaded artificial bone and autologous bone mixed grafting in the treatment of infected nonunion in different parts

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121165
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-03-26
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Observation group for treatment of infectious nonunion of different bone segments:None

Sponsors

Yuebei People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Medical history (persistent pain after fracture, local redness, swelling or sinus tract formation); 2.Imaging findings (X-ray shows no callus formation at the fracture site and a clear fracture line, CT reveals sclerosis or pseudoarthrosis at the fracture site); 3.Microbiological testing (cultivation of lesion secretions or intraoperative tissue biopsy to identify the causative pathogen); 4.The infected sites are the humerus of the upper limb, the tibia or femur of the lower limb (excluding special sites such as the spine and pelvis); 5.Age 18-70 years, able to tolerate the second stage surgery and 12-month postoperative follow-up; 6.The patient and their family fully understand the research protocol, sign the informed consent form, and commit to cooperating in completing all examinations and follow-ups.

Exclusion criteria

Exclusion criteria: 1.Impaired function of vital organs: cardiac function classification = III, liver and kidney failure (Child-Pugh C grade, serum creatinine > 200 µmol/L), coagulation dysfunction (INR > 1.5 or APTT > 60 seconds); 2.Allergic to recombinant human BMP-2, calcium phosphate artificial bone, vancomycin/meropenem (antibiotics used in antibiotic-loaded artificial bone); 3.Psychiatric disorders (unable to comply with follow-up), bone defects > 6cm (exceeding the scope of mixed bone grafting repair), incomplete clinical data; 4.Combine active tuberculosis, malignant tumors, and immunodeficiency diseases (such as HIV infection);

Design outcomes

Primary

MeasureTime frame
Bone healing rate;Infection control rate;Material adverse reaction;

Secondary

MeasureTime frame
Bone Metabolism Indicators;Clinical Functional Scoring;Complication rate;Bone healing time;

Countries

China

Contacts

Public ContactZhou Longze

Yuebei People’s Hospital

493461793@qq.com+86 751 6913623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026